论文部分内容阅读
目的比较氨溴索和肺表面活性物质(PS)治疗新生儿呼吸窘迫综合征(NRDS)的效果。方法将47例NRDS随机分为两组,氨溴索组22例,30mg/(kg·d),分3～4次静脉给药,连用3d;PS组25例,首剂200mg/kg,气管内给药,重复100mg/kg,间隔6h以上,最多用3次。结果氨溴索组治愈13例占59.18%,好转3例占13.6%,死亡6例占27.3%;PS组治愈18例占72%,好转2例占8%,死亡5例占20%。两组比较,PS组疗效高于氨溴索组,但差异无统计学意义(χ2=0.87,P>0.05),死亡率比较差异无统计学意义(χ2=0.35,P>0.05)。结论氨溴索与PS治疗NRDS的效果相当。
Objective To compare the efficacy of ambroxol and pulmonary surfactant (PS) in the treatment of neonatal respiratory distress syndrome (NRDS). Methods 47 cases of NRDS were randomly divided into two groups, ambroxol group 22 cases, 30mg / (kg · d), divided into 3 to 4 times intravenously, used 3d; PS group 25 cases, the first dose of 200mg / kg, trachea Internal administration, repeated 100mg / kg, interval 6h above, up to 3 times. Results The cure rate of ambroxol group was 59.18% in 13 cases, 13.6% in 3 cases and 6 cases in 27.2%. In PS group, 18 cases were cured in 72 cases, 2 cases improved in 8 cases and 5 cases died in 20%. There was no significant difference between the two groups (χ2 = 0.87, P> 0.05). There was no significant difference in mortality between the two groups (χ2 = 0.35, P> 0.05). Conclusions Ambroxol is equivalent to PS in the treatment of NRDS.